Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 4/2016

01-04-2016 | Editorial

Natural killer cells, ageing and cancer

Authors: Elissaveta Naumova, Graham Pawelec, Anastasiya Mihaylova

Published in: Cancer Immunology, Immunotherapy | Issue 4/2016

Login to get access

Abstract

Natural killer (NK) cells are key components of innate immunity and substantially contribute to anti-tumor immune responses. The role of NK cells in immune surveillance is linked to many aspects of NK cell biology, but the age of the animal being studied or the human under treatment is rarely taken into account. The solicited reviews constituting a collection of papers presented here as a “Symposium-in-Writing” on the topic of NK cells, ageing and cancer were inspired by the increasing knowledge of NK cell biology and genetics, and emerging data on their impact in the clinic (disease associations and therapies), together with the realization that older individuals also differ from younger ones regarding innate as well as adaptive immunity.
Literature
2.
4.
go back to reference Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, Casado JG, Morgado S, Duran E, Solana R, Tarazona R (2015) Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? Cancer Immunol Immunother. doi:10.1007/s00262-015-1720-6 PubMed Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, Casado JG, Morgado S, Duran E, Solana R, Tarazona R (2015) Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? Cancer Immunol Immunother. doi:10.​1007/​s00262-015-1720-6 PubMed
5.
go back to reference Pietra G, Vitale C, Pende D, Bertaina A, Moretta F, Falco M, Vacca P, Montaldo E, Cantoni C, Mingari MC, Moretta A, Locatelli F, Moretta L (2015) Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunol Immunother. doi:10.1007/s00262-015-1744-y PubMed Pietra G, Vitale C, Pende D, Bertaina A, Moretta F, Falco M, Vacca P, Montaldo E, Cantoni C, Mingari MC, Moretta A, Locatelli F, Moretta L (2015) Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunol Immunother. doi:10.​1007/​s00262-015-1744-y PubMed
6.
go back to reference Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C (2016) Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. doi:10.1007/s00262-016-1792-y PubMed Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C (2016) Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. doi:10.​1007/​s00262-016-1792-y PubMed
7.
go back to reference Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T (2015) NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. doi:10.1007/s00262-015-1761-x PubMed Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T (2015) NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. doi:10.​1007/​s00262-015-1761-x PubMed
Metadata
Title
Natural killer cells, ageing and cancer
Authors
Elissaveta Naumova
Graham Pawelec
Anastasiya Mihaylova
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 4/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1817-6

Other articles of this Issue 4/2016

Cancer Immunology, Immunotherapy 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine